Gain Therapeutics, Inc. (GANX)

NASDAQ

$2.10

$-0.02

(-0.94%)

Gain Therapeutics, Inc. (GANX) Live Price Chart

Page last updated: 2026-04-21 21:13:00

Key Market Data

Market Cap	$88.67M
Open	$2.14
High	$17.93
Low	$0.89
Previous Close	$2.12
Price Change	$-0.02
Percentage Change	-0.94%
Volume	446K

Gain Therapeutics, Inc. (GANX) Stock Price Today

Gain Therapeutics, Inc. (GANX) is currently trading at $2.10 as of 2026-04-21 21:13:00, reflecting a -0.94% move ($-0.02) from the previous close.

In the short term, the stock has returned +11.06% over the past four weeks. Over the last 12 months, Gain Therapeutics, Inc. has recorded a +20.63% price change, indicating a Strong performance relative to the broader market.

Gain Therapeutics, Inc. (GANX) 7-Day Stock Price Changes

Over the past seven days, Gain Therapeutics, Inc. has traded within a short-term range shaped by market sentiment in the PHARMACEUTICAL PREPARATIONS sector. During this period, the stock moved from its previous closing price of $1.91 to the latest recorded price of $2.10, reflecting an intraday change of -0.94%. Daily movements highlight shifts in trading volume (445,627), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, GANX has delivered a +11.06% return over the past month and a +20.63% change in the last 12 months, indicating a Strong trend relative to its broader sector peers.

How to Buy Gain Therapeutics, Inc. (GANX)

You can buy and trade GANX on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for GANX and Execute Your Trade

Open the trading page, enter GANX in the search bar, select the amount of GANX you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Gain Therapeutics, Inc. (GANX)?

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Gain Therapeutics, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	21
Sector	PHARMACEUTICAL PREPARATIONS
Company Website	https://www.gaintherapeutics.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Gain Therapeutics, Inc.?

The latest trading price for Gain Therapeutics, Inc. (Common Stock) is $ 2.10, compared with a previous closing price of $ 2.12. That means the stock has moved -0.94% so far today. Intraday price updates and recent trading activity for GANX can be tracked on the live chart and quote section on this page.

2.Is Gain Therapeutics, Inc. stock going up or down?

Looking at recent performances, GANX has returned +11.06% over the past month, +6.01% over the last six months and +20.63% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe Strong price momentum for Gain Therapeutics, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does GANX currently sit relative to its 52-week high and low?

In the most recent 52-week period, Gain Therapeutics, Inc. has traded between a low of $ 1.41 and a high of $ 4.34. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether GANX is currently nearer the top or the bottom of its one-year trading band.

4.How is Gain Therapeutics, Inc. classified by sector and industry?

Gain Therapeutics, Inc. is classified in the PHARMACEUTICAL PREPARATIONS sector. In practice, this means Gain Therapeutics, Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing GANX’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the PHARMACEUTICAL PREPARATIONS sector could influence Gain Therapeutics, Inc.’s performance.

5.Where is Gain Therapeutics, Inc. listed and how large is it by market value?

Gain Therapeutics, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 88.67M, the company is classified as a Small-cap stock. Market cap gives a quick sense of Gain Therapeutics, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does GANX's EPS tell investors about its profitability?

Trailing-twelve-month EPS of $ -0.47 summarises how much profit Gain Therapeutics, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Gain Therapeutics, Inc.'s financial performance over time?

To follow Gain Therapeutics, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how GANX is performing and how the market is responding.

8.When is Gain Therapeutics, Inc. expected to report earnings?

Gain Therapeutics, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for GANX, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Gain Therapeutics, Inc.'s earnings reports?

Gain Therapeutics, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether GANX is meeting, beating or missing expectations.

10.How can I stay informed about Gain Therapeutics, Inc.'s results and guidance?

You can stay up to date on Gain Therapeutics, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for GANX on this page helps you see how new information is being reflected in the stock.

11.Does Gain Therapeutics, Inc. pay a regular cash dividend to its shareholders?

Gain Therapeutics, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor GANX's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for GANX?

Based on the latest earnings data, GANX has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Gain Therapeutics, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Gain Therapeutics, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Gain Therapeutics, Inc.?

Gain Therapeutics, Inc. is a publicly traded company in the PHARMACEUTICAL PREPARATIONS industry within the PHARMACEUTICAL PREPARATIONS sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is GANX valued in terms of P/E ratio and EPS?

Gain Therapeutics, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -0.47. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Gain Therapeutics, Inc.'s earnings. Comparing GANX's P/E and EPS to those of other PHARMACEUTICAL PREPARATIONS companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Dell Technologies Inc.

DELL

The Mosaic Company

MOS

Hims & Hers Health, Inc.

HIMS

Ginkgo Bioworks Holdings, Inc.

DNA

Norwegian Cruise Line Holdings Ltd.

NCLH

Top Gainers

Browse today's leading gainers in the US stock market

Faraday Future Intelligent Electric Inc.

FFAI

Electro-Sensors Inc.

ELSE

Baiya International Group Inc.

BIYA

Local Bounti Corporation

LOCL

Dreamland Limited

TDIC

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

GANX-to-USD Calculator

Amount

GANX

USD

1 GANX = 2.099 USD